BiotechTube
ParcelBio

ParcelBio

San Francisco, United States· Est.
parcelbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $30M

Overview

ParcelBio is an early-stage biotech firm utilizing AI to revolutionize the discovery of RNA therapeutics. Founded in 2020 and headquartered in San Francisco, the company is developing a proprietary platform to identify promising drug candidates more efficiently than traditional methods. As a private, pre-revenue platform company, it is positioned to capitalize on the rapidly expanding RNA medicine market. Its success will depend on validating its AI technology, advancing programs into the clinic, and securing strategic partnerships or funding.

RNA & Gene Therapy

Technology Platform

AI-powered platform for the discovery and design of novel RNA therapeutics, accelerating candidate identification and optimization.

Funding History

2
Total raised:$30M
Series A$25M
Seed$5M

Opportunities

The RNA therapeutics market is large and growing rapidly, creating demand for more efficient discovery tools.
ParcelBio's AI platform could significantly reduce the time and cost of bringing new RNA medicines to market, attracting partnership interest from large pharmaceutical companies.
Successfully validating the platform could position the company as a key enabler in the next wave of genetic medicine.

Risk Factors

The AI platform may fail to generate clinically viable candidates, representing a core technical risk.
The company operates in a highly competitive landscape with numerous well-funded AI-biotech rivals.
As a pre-revenue startup, it is dependent on external capital, making it vulnerable to shifts in the biotech funding environment.

Competitive Landscape

ParcelBio competes in the crowded AI-driven drug discovery sector, facing competition from pure-play AI platform companies (e.g., Exscientia, Recursion), large biopharma internal initiatives, and other RNA-focused biotechs. Differentiation will depend on the unique predictive power of its models for RNA biology, the quality of its training data, and its ability to rapidly translate computational designs into validated leads.

More companies in RNA Therapeutics (non-mRNA) →More companies in United States →